0001209191-23-050195.txt : 20230920 0001209191-23-050195.hdr.sgml : 20230920 20230920175409 ACCESSION NUMBER: 0001209191-23-050195 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230919 FILED AS OF DATE: 20230920 DATE AS OF CHANGE: 20230920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Donald Allen CENTRAL INDEX KEY: 0001620013 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 231267408 MAIL ADDRESS: STREET 1: C/O PRYOR CASHMAN LLP STREET 2: 7 TIMES SQUARE CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-19 0 0001419041 Forte Biosciences, Inc. FBRX 0001620013 Williams Donald Allen C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BUILDING 6 DALLAS TX 75247 1 0 0 0 0 Stock Option (right to buy) 0.80 2023-09-19 4 A 0 25000 0.00 A 2033-09-19 Common Stock 25000 25000 D Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact 2023-09-20